The Peptide NewsroomPeptide research, industry and supply-chain headlines

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Three-dimensional structure render: Semaglutide-bound Glucagon-Like Peptide-1 (GLP-1) Receptor in Complex with Gs protein
Structure: RCSB PDB entry 7KI0 (CC0 1.0 public domain). Rendering: RCSB PDB.

Semaglutide is a GLP-1 receptor agonist sold as Ozempic and Wegovy, used in type 2 diabetes and obesity management. The published record on it is now large enough to separate what has been measured from what is still being argued about.

How much weight came off

A University of Alberta research team writing in The Conversation reports that GLP-1 medications reduced body weight by an average of 15 percent when used weekly for 68 weeks alongside lifestyle interventions. The same team notes that semaglutide acts on the brain to increase fullness and decrease appetite, and that weight loss is only one measure of how well the drugs work.

Why some people respond and some do not

The Alberta group is investigating whether genetics, body composition, microbiota, age and sex explain the spread in response. Their review of studies on GLP-1 therapies and energy utilization found only a few looking at resting energy use, with results they describe as neutral or inconclusive.

The brain question

Researchers from Gothenburg and Copenhagen, reviewing the evidence at the invitation of Science, report that patient record analyses have found an association between GLP-1 treatment and reduced dementia risk in people with type 2 diabetes, while cautioning that observational data cannot establish cause. In Novo Nordisk's EVOKE and EVOKE+ trials, semaglutide failed to slow progression of early Alzheimer's disease, even though several biological markers shifted.

Muscle, and what might sit alongside it

The same review flags that rapid weight loss can reduce muscle mass, a particular concern in older and physically frail patients. A UC Berkeley team testing an experimental compound called TOFA reported that obese mice lost fat without significant loss of lean mass, and that combining TOFA with semaglutide produced greater improvements in weight, glucose and triglycerides than either alone. That work is entirely in mice, and the authors say safety and effectiveness in humans are not established.

What Isn't Established

Whether semaglutide changes resting energy expenditure in people, in either direction. Whether it protects cognition in anyone, since the dementia signal is observational and the Alzheimer's trial was negative. Whether any add-on can spare muscle in humans, since the TOFA data stop at mice.

Where the evidence stands

The weight and metabolic outcomes rest on large human trials. The brain and energy-metabolism questions rest on observational data, one failed trial, and studies still recruiting.

Sources: RSS.app — Renewal bundle (read), ScienceDaily — Pharmacology (read), RSS.app — Renewal bundle (read), ScienceDaily — Pharmacology (read), ScienceDaily — Pharmacology (read).

Filed under: explainer, glp-1, muscle

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Sermorelin Goes Mainstream on Telehealth, but the Dosing and Efficacy Data Are Missing

Sermorelin, a peptide that stimulates growth-hormone release, is now sold nationally through Hims and Hers as part of its compounded Peptides+ platform. Neither the company nor the outside experts quoted can point to human outcome trials or an established dose.

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Kemin's Filipa Quintela told Nutritional Outlook at SupplySide Global that positive aging, GLP-1 support through Slendesta, and gut health via the Gutopia platform will shape the supplier's 2027 development. She also put American lutein intake at around 2 mg a day against an optimal 10 mg.

Ingredient Supplier Kemin Puts GLP-1 Companion Nutrition at the Center of Its 2027 Outlook

At SupplySide Global, ingredient developer Kemin outlined a 2027 wellness outlook built on GLP-1 companion nutrition, gut health, and positive aging, with FloraGLO Lutein repositioned toward cognition. No trial data or outcome figures appear anywhere in the coverage, which makes this a supplier forecast rather than new evidence.